VCEL Vericel Corp
FY2025 10-K
Vericel Corp (VCEL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care markets
- • New product launch: MACI Arthro arthroscopic delivery system approved August 2024 and commercially available Q3 2024 with custom instruments
Management Discussion & Analysis
- • Revenue not explicitly stated, but sales volume increase indicated by accounts receivable growth and higher net income $16.5M in 2025 vs $10.4M in 2024
- • Net income $16.5M (2025), operating expenses include $38.8M stock compensation, no explicit margin % reported
Risk Factors
- • Regulatory risk: potential penalties from FDA or state agencies for off-label promotion or anti-kickback/anti-bribery law violations
- • Geopolitical risk: supply disruption of NexoBrid due to Middle East conflicts or China-Taiwan tensions, impacting commercial success
Financial SummaryXBRL
Revenue
$276M
Net Income
$17M
Gross Margin
74.4%
Operating Margin
4.0%
Net Margin
6.0%
ROE
4.7%
Total Assets
$488M
EPS (Diluted)
$0.32
Operating Cash Flow
$52M
Source: XBRL data from Vericel Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vericel Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.